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The introduction of tyrosine kinase inhibitors in the treatment of BCR-ABL1-rearranged malignancies has
revolutionized therapy, but the prognosis for acute leukemias remains suboptimal. In this issue of Cancer
Cell, Bueno et al. (2008) add a new dimension to the regulation of ABL1 expression. The authors demonstrate
that ABL1 is a direct target of miR-203, miR-203 is silenced by genetic and epigenetic mechanisms in hema-
topoieticmalignancies expressing either ABL1 or BCR-ABL1, and restoration ofmiR-203 expression reduces
ABL1 and BCR-ABL1 levels and inhibits cell proliferation. These findings may have broad implications for
mechanisms underlying malignant transformation in hematopoietic and other malignancies.MicroRNAs (miRNAs) are noncoding
RNAs that regulate many cellular func-
tions including cell proliferation, differenti-
ation, and apoptosis by silencing specific
target genes through translational repres-
sion or direct mRNA degradation (Am-
bros, 2004). Although the detailed func-
tions of the growing number of miRNAs
identified in the mammalian genome are
far from being completely characterized,
recent studies have indicated that de-
regulated expression of specific miRNAs
that modulate expression of oncogenes
and tumor suppressors is associated
with the development of malignancies,
and specific miRNA expression signa-
tures can be used to effectively classify
human tumors (Lu et al., 2005). Although
genome copy-number changes are asso-
ciated with altered levels of miRNA ex-
pression in various human malignancies
(Zhang et al., 2006), recent data suggest
that miRNA inactivation by epigenetic
mechanisms plays an important role
as well, and re-expression of certain
miRNAs by drugs that modulate epige-
netic changes can lead to downregulation
of target oncogenes (Fazi et al., 2007).More than 40 years ago, the Philadel-
phia (Ph) chromosome was identified by
Nowell and Hungerford. The Ph chromo-
some is a product of the t(9;22), which
fuses the Abelson kinase gene (ABL1)
from chromosome 9 with the breakpoint
cluster region (BCR) from chromosome
22 that expresses the BCR-ABL1 fusion
protein: a constitutively active tyrosine
kinase. The BCR-ABL1 fusion oncopro-
tein is a hallmark of chronic myelogenous
leukemia (CML) and is also present in
a fraction of B progenitor acute lympho-
blastic leukemia (ALL) cases that have
a particularly poor prognosis. Aberrant
expression of the wild-type ABL1 onco-
gene may also be associated with the de-
velopment of hematopoietic malignancies
including T cell lymphomas (Ren, 2005).
While the development of tyrosine kinase
inhibitors (TKIs) like imatinib mesylate
have revolutionized treatment of BCR-
ABL1-rearranged leukemias, it has be-
come increasingly clear in recent years
that TKI treatment alone will not be cura-
tive in many cases, particularly in acute
leukemias with BCR-ABL1 rearrange-
ment. Thus, further dissection of theCancerregulatory networks that drive BCR-
ABL1-induced malignant transformation
may help to identify other novel therapeu-
tic approaches that complement TKI
treatment.
In this issue of Cancer Cell, a study by
Bueno et al. (2008) begins to elucidate
the role of silenced miRNA expression in
the regulation of BCR-ABL1-rearranged
leukemias and T cell lymphomas express-
ing ABL1. Using comparative genomic
hybridization (CGH) analysis of murine g
radiation-induced lymphomas, the au-
thors identify loss of heterozygosity of
a fragile 7 Mb chromosomal region on
murine chromosome 12, a region coding
for approximately 12% (52 miRNAs) of
the mammalian miRNAome known to
date. miRNA profiling revealed decreased
expression of one of the region’s miRNAs:
miR-203. Analysis of the miR-203 pro-
moter demonstrated that miR-203 is si-
lenced not only by genetic loss of one
allele but also epigenetically by promoter
CpG hypermethylation in the remaining
DNA copy (Figure 1). Next, the authors as-
sessed putative miR-203 targets and
identified the ABL1 tyrosine kinaseCell 13, June 2008 ª2008 Elsevier Inc. 467
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PreviewsFigure 1. Model of ABL1 and BCR-ABL1 Regulation by miR-203
miR-203 is silenced by both genetic and epigenetic mechanisms in lymphomas expressing high levels of
ABL1 and in BCR-ABL1-rearranged leukemias. The loss of MiR-203 leads to elevated expression of its
direct targets ABL1 and BCR-ABL1, which enhances cell proliferation.oncogene as being directly regulated by
miR-203. Re-expression ofmiR-203 leads
to decreased aberrant ABL1 expression in
human T cell tumor cell lines, which was
accompanied by an antiproliferative effect
in these cells. Of significant interest, the
authors demonstrate epigenetic silencing
of miR-203 by CpG hypermethylation in
human BCR-ABL1-rearranged leukemia
cells, but not in leukemia cells without
the BCR-ABL1 rearrangement, suggest-
ing a specific pressure to downregulate
miR-203 expression in Ph-positive malig-
nancies. Furthermore, the authors find
that re-expression of miR-203 leads to
a decrease of BCR-ABL1 expression and
a decrease in the proliferation rate of Ph-
positive human CML cell lines. A similar
effect was observed after treatment with
drugs that inhibit DNAmethylation, includ-
ing 50-azacytidine and 4-phenylbutyrate.
Treatment of Ph-positive CML cell lines
resulted in demethylation of the miR-203
promoter region, restoration of miR-203
expression, and a reduction of both ABL1
and BCR-ABL1 expression. These data
demonstrate that genetic and epigenetic
mechanisms participate in transcriptional468 Cancer Cell 13, June 2008 ª2008 Elsevsilencing of miR-203, which is associated
with elevated expression of ABL1 or
BCR-ABL1 inhematopoieticmalignancies.
In this context, miR-203 seems to modify
leukemia cell biology by directly regulating
a leukemogenic fusion oncoprotein, and
restoration of miR-203 expression sup-
presses proliferation of these tumor cells.
Interestingly, miR-203 has recently been
shown to be involved in regulating the bal-
ance between stem cell proliferation and
terminal differentiation in the skin (Yi et al.,
2008). The antiproliferative effect of miR-
203 in epidermal stem cells is mediated
through the direct repression of p63 ex-
pression. Thus, miR-203 may be a general
inhibitor of progenitor and stem cell prolif-
eration in normal development, and ge-
netic and epigenetic silencing of miR-203
contributes to uncontrolled proliferation in
certain cancers.
This study has several important impli-
cations that may impact both therapeutic
approaches and oncogenesis. First, it
demonstrates a new mechanism regulat-
ing aberrant ABL1 and BCR-ABL1 ex-
pression. This may be particularly impor-
tant for therapies incorporating TKIs, asier Inc.BCR-ABL1 expression levels may influ-
ence drug sensitivity (Shah and Sawyers,
2003). Restoration of silenced miR-203
expression—potentially either directly or
through the application of demethylating
epigenetic drugs such as decitabine—
might represent a novel therapeutic ap-
proach in ALL and CML cases carrying
the BCR-ABL1 fusion and T cell lym-
phoma/leukemias with high-level ABL1
expression. As loss of the miR-203-con-
taining gene region is observed during
disease progression in CML blast crisis
(Sercan et al., 2000), it is possible that dis-
ease progression may be accompanied
by inactivation of tumor suppressor genes
in this region including miR-203. How-
ever, it is likely that other mechanisms
may also be involved in CML progression
to blast crisis, such as loss of the tran-
scription factor Ikaros found in many
BCR-ABL1-rearranged ALLs as well as
in a significant fraction of CML blast crisis
cases (Mullighan et al., 2008). Also, acti-
vation of the Wnt pathway in myeloid pro-
genitor cells accompanies CML progres-
sion (Jamieson et al., 2004). A critical
next step in the biology of CML blast crisis
will be to further dissect the significance,
frequency, and potential interdepen-
dence of each of these mechanisms.
The findings of Bueno et al. (2008) also
have potential implications more broadly
for the regulation of fusion oncogenes in
leukemia development. The demonstra-
tion that miRNAs can be lost through ge-
netic and epigenetic mechanisms and
that these miRNAs can directly regulate
expression of fusion oncoproteins sug-
gests another layer of complexity that
may modify tumor biology. Future studies
will continue to shed light on the extent to
which miRNA-mediated regulation of fu-
sionorotheroncogeneexpressionisacen-
tral part of the oncogenic process and
whether this new dimension of regulation
plays a critical role in tumor progression
or drug resistance. These newly defined
regulatory mechanisms and added layer
of complexity will hopefully provide an-
other avenue for therapeutic intervention.
REFERENCES
Ambros, V. (2004). Nature 431, 350–355.
Bueno, M.J., Pe´rez de Castro, I., Go´mez de Ce-
dro´n, M., Santos, J., Calin, G.A., Cigudosa, J.C.,
Croce, C.M., Ferna´ndez-Piqueras, J., and Malum-
bres,M. (2008). CancerCell13, this issue, 496–506.
Cancer Cell
PreviewsFazi, F., Racanicchi, S., Zardo, G., Starnes, L.M.,
Mancini, M., Travaglini, L., Diverio, D., Ammatuna,
E., Cimino, G., Lo-Coco, F., et al. (2007). Cancer
Cell 12, 457–466.
Jamieson, C.H., Ailles, L.E., Dylla, S.J., Muijtjens,
M., Jones, C., Zehnder, J.L., Gotlib, J., Li, K.,
Manz, M.G., Keating, A., et al. (2004). N. Engl. J.
Med. 351, 657–667.
Lu, J., Getz, G., Miska, E.A., Alvarez-Saavedra, E.,
Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B.L.,The Ups and Dow
Tumor Suppressio
Marilyn D. Resh1,*
1Cell Biology Program, Memorial Sloan-Ketter
*Correspondence: m-resh@ski.mskcc.org
DOI 10.1016/j.ccr.2008.05.011
Tight control of the tyrosine kinase a
issue of Molecular Cell, Oneyama e
known as PAG) can suppress c-Src-
tering c-Src within lipid rafts. Cbp i
c-Src. However, the authors show t
suggest that Cbp is a tumor supp
progression.
Src family kinases (SFKs) are membrane-
bound tyrosine protein kinases that share
a common domain structure. The found-
ing member of the family, Src, was origi-
nally identified as a retroviral oncoprotein
that induces transformation of avian cells
and sarcoma formation in chickens. It is
now well established that the cellular
proto-oncoprotein c-Src plays an influen-
tial role in human cancers. Increased
levels of c-Src protein and/or tyrosine
kinase activity have been detected in mul-
tiple tumor types, including breast, colon,
lung, head and neck, and pancreatic can-
cers (Ishizawar and Parsons, 2004). Src
activation promotes tumor progression,
metastasis, and angiogenesis, while
blockade of Src kinase activity results in
decreased tumor cell proliferation, migra-
tion, and invasion. These findings have
served as an impetus for the development
of Src kinase inhibitors, several of which
are currently in clinical trials for thera-
peutic treatment of a variety of human
cancers.Mak, R.H., Ferrando, A.A., et al. (2005). Nature 435,
834–838.
Mullighan, C.G., Miller, C.B., Radtke, I., Phillips,
L.A., Dalton, J., Ma, J., White, D., Hughes, T.P.,
Le Beau, M.M., Pui, C.H., et al. (2008). Nature
453, 110–114.
Ren, R. (2005). Nat. Rev. Cancer 5, 172–183.
Sercan, H.O., Sercan, Z.Y., Kizildag, S., Undar, B.,
Soydan, S., and Sakizli, M. (2000). Leuk. Lym-
phoma 39, 385–390.ns of Src Regulatio
n by Cbp
ing Cancer Center, 1275 York Avenue, New Yo
ctivity of c-Src is critical for regulating
t al. (2008a) report that the membran
mediated cell transformation and tum
s also a raft-associated binding part
hat Cbp-mediated Src suppression i
ressor whose expression is downr
The kinase activity of SFKs is tightly
regulated. A critical negative regulatory
tyrosine resides in the C-terminal tail of
all SFKs (Tyr527 in c-Src). When Tyr527
is phosphorylated, c-Src is inactive.
Dephosphorylation of Tyr527, or mutation
of Tyr527 to Phe, activates c-Src and
induces cellular transformation. Crystallo-
graphic studies have revealed that the
structural basis for c-Src regulation invol-
ves intramolecular interactions between
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Phosphorylation of Cbp by SFKs serves
to recruit Csk to membrane-bound Cbp.
Csk then phosphorylates and conse-
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SFKs.
Given this neatly intertwined set of re-
actions, one might assume that the ability
of Cbp to regulate SFKs is dependent on
Csk. However, a recent paper in Molecu-
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et al., 2008b). The authors first noted
that levels of endogenous Cbp mRNA
and protein were reduced when activated
c-Src was expressed. They then made
the seminal observation that overexpres-
sion of exogenous Cbp reversed the
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